# Lack of iNKT cells in patients with combined immune deficiency due to hypomorphic RAG mutations

Ponpan Matangkasombut, Muriel Pichavant, Doris E Saez, Silvia Giliani, Evelina Mazzolari, Andrea Finocchi, Anna Villa, Cristina Sobacchi, Patricia Cortes, Dale T Umetsu and Luigi D. Notarangelo

Articles on similar topics can be found in the following Blood collections
    Brief Reports (1654 articles)
    Clinical Trials and Observations (3722 articles)
    Immunobiology (5022 articles)

Information about reproducing this article in parts or in its entirety may be found online at:
    http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#repub_requests

Information about ordering reprints may be found online at:
    http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#reprints

Information about subscriptions and ASH membership may be found online at:
    http://bloodjournal.hematologylibrary.org/site/subscriptions/index.xhtml

**Lack of iNKT cells in patients with combined immune deficiency due to hypomorphic *RAG* mutations**

**Running title:** iNKT cells in Omenn syndrome

Ponpan Matangkasombut[1*], Muriel Pichavant[1*], Doris E. Saez[2], Silvia Giliani[3], Evelina Mazzolari[3], Andrea Finocchi[4], Anna Villa[5,6], Cristina Sobacchi[5,6], Patricia Cortes[2], Dale T Umetsu[1#], Luigi D. Notarangelo[1#]

[1]Division of Immunology, Children's Hospital Boston, Harvard Medical School, Boston, Massachusetts, USA. [2]Immunology Institute, Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA, [3]Department of Pediatrics and "Angelo Nocivelli" Institute for Molecular Medicine, University of Brescia, Italy, [4]Department of Pediatrics, Tor Vergata University, Rome, Italy, [5]Istituto Tecnologie Biomediche, Consiglio Nazionale delle Ricerche, Segrate, Milan, Italy, [6]Istituto Clinico Humanitas, Rozzano, Milan Italy

[*#]These authors contributed equally.

**Corresponding author:**
Luigi D. Notarangelo
Division of Immunology, Children's Hospital
Karp Building, 9th floor, Room 09210
1 Blackfan Circle, Boston, MA 02115 – U.S.A.
e-mail: luigi.notarangelo@childrens.harvard.edu
phone: (617)-919-2276
FAX: (617)-730-0709

**Abstract**

Hypomorphic mutations of the *RAG* genes in humans are associated with a spectrum of clinical and immunological presentations that range from T⁻ B⁻ Severe Combined Immune Deficiency (SCID) to Omenn syndrome. In most cases, residual V(D)J recombination activity allows for development of few T cell clones, that expand in the periphery and infiltrate target organs, resulting in tissue damage.

Invariant Natural Killer T (iNKT) cells play an important immunoregulatory role and have been associated with protection against autoimmunity. We now report on five unrelated cases of combined immune deficiency due to hypomorphic *RAG* mutations, and demonstrate the absence of iNKT cells in all five patients. These findings suggest that lack of this important immunoregulatory cell population may contribute to the pathophysiology of Omenn syndrome.

**Introduction**

Omenn syndrome (OS) is a combined immunodeficiency characterized by early-onset erythrodermia, lymphadenopathy, hepatosplenomegaly, and severe infections. Patients with OS have a variable number of autologous, oligoclonal, and activated T cells that infiltrate and damage target tissues[1,2].

OS may be due to heterogeneous gene defects that impair, but do not abolish, thymic T cell development. In particular, hypomorphic mutations of the *RAG1* or *RAG2* genes, involved in V(D)J recombination, are a common cause for OS[3-5]. The same defects may lead to a spectrum of clinical and immunological phenotypes that also include typical T⁻ B⁻ SCID or leaky SCID with residual presence of activated T cells, in the absence of typical features of OS[4,6].

The clinical and pathological features of OS are suggestive of T-cell mediated autoimmunity. In keeping with this hypothesis, we have found that expression of AIRE and of AIRE-dependent tissue-specific transcripts is reduced in the thymus from patients with OS, possibly contributing to impaired central tolerance[7]. In addition, defects of regulatory T cells have been also hypothesized in patients with OS[8]. Both abnormalities have been confirmed in a newly generated murine model of OS[9]. However, the possible contributory role of other immunomodulatory components in determining the phenotype of OS has not been carefully evaluated.

NKT cells represent a population of cells with significant immunomodulatory properties[10]. In humans, most NKT cells recognize glycolipids presented in the context of CD1d molecules and express NK cell markers along with an invariant T-cell receptor

(TCR) with a Vα24-Jα18 rearrangement. NKT cells expressing the invariant TCR (iNKT) can be identified by using α-galactosylceramide (α-GalCer)-loaded CD1d tetramers[11]. iNKT cells are generated in the thymus from CD4[+] CD8[+] thymocytes that rearrange the invariant TCR and are directed to the NKT lineage following cognate interactions with CD1d-expressing cortical thymocytes[12,13]. Therefore, NKT cells development is absolutely dependent on V(D)J recombination, consistent with the observation that iNKT cells are severely reduced in a *Rag2* knock-in mouse model of OS[9].

In this study, we provide the first evidence that iNKT cells are absent in peripheral blood of patients with hypomorphic *RAG* mutations, a situation where substantial numbers of autoreactive T cells develop. We speculate that the absence of iNKT cells may contribute to the pathophysiology of OS.

**Materials and Methods**

*Patients*

Five unrelated patients with hypomorphic *RAG* defects were studied; four of them (Pt. #1, 2, 3 and 5) had typical OS, whereas Pt. #4 had the phenotype of T[+]B[-] leaky SCID (Table 1). Informed consent was obtained according to protocols approved by Children's Hospital, Boston; the Department of Pediatrics, University of Brescia, Italy; and the Department of Pediatrics, Tor Vergata University of Rome, Italy. Maternal T-cell engraftment was ruled out by molecular analysis using microsatellite markers.

*Mutation analysis*

Genomic DNA was extracted by standard procedures from blood samples. The single exons of *RAG* genes were amplified by PCR using thirteen pairs of overlapping primers, and the presence of mismatches was revealed by denaturing HPLC (DHPLC). When mismatches were found, direct sequencing was performed using the Big Dye Terminator kit (Applied Biosystems) on an ABI PRISM 3130 automatic sequencer (Applera).

*Immunophenotyping of peripheral blood mononuclear cells (PBMC)*

PBMC were isolated by density gradient centrifugation using Histopaque 1077 (Sigma-Aldrich). Immunophenotyping was performed by flow cytometry (BD FACSCanto) using the following anti-human antibodies: FITC-conjugated anti-CD4 (BD Pharmingen), FITC-conjugated anti-V$\alpha$24 (Immunotech), FITC-conjugated mouse IgG1 isotype control (eBioscience), PE-conjugated anti-V$\beta$11 (Immunotech), PE-conjugated anti-invariant NK T cells (clone 6B11, BD Pharmingen), PE-conjugated mouse IgG2a isotype control (BD Pharmingen), PE-conjugated mouse IgG1 (BD Pharmingen), PE-conjugated PBS57-loaded human CD1d tetramer or PE-conjugated unloaded human CD1d tetramer (National Institutes of Health Tetramer Facility), PE-Cy5 conjugated anti-CD45 (eBioscience), Alexa750-conjugated anti-CD3 (eBioscience). Data were analyzed using the FlowJo 8.3.3 software. Leukocytes were gated on CD45$^+$ cells. Lymphocytes were gated based on forward and side scatter. CD3$^+$ lymphocytes were then analyzed for expression of invariant T cell receptor (iTCR) of iNKT cells as determined by staining with PBS57-loaded CD1d tetramer (in comparison to unloaded CD1d tetramers). The percentage of iNKT cells in patients 3 and 5 was analyzed also by anti-V$\alpha$24 and anti-V$\beta$11 antibodies as well as by anti-invariant NKT cells (clone 6B11) antibody.

*V(D)J recombination analysis*

V(D)J recombination activity of the human RAG1 mutants G139R, G392E, and L732fs was assessed by a plasmid-based colony forming assay by co-transfecting into 293T cells the expression vectors of wild-type hRAG1 and wild-type hRAG2 (or of the mutants) with substrates pGG49 and pGG51 to allow to measure signal joints and coding joins formation, respectively[14].

**Results and discussion**

The five patients are representative of the spectrum of clinical and laboratory manifestations associated with hypomorphic *RAG* mutations. In all cases, the presence of at least one hypomorphic *RAG* allele allowed for residual T cell development, with accumulation of activated and anergic autologous T cells. The M435V mutation in the *RAG1* gene of patient 1 falls within the nonamer-binding domain, and has been previously reported in OS[6]. The G392E mutation of patient 3 involves the first residue of the GGRPR motif of the nonamer-binding domain (NBD) and had not been previously reported. While double mutations of murine GG 389-390 (corresponding to human residues 392-393) have a dramatic impact on nonamer binding[15], single aminoacid substitutions in the NBD allow for residual V(D)J recombination activity and have been identified in patients with OS[3,16]. The R561H mutation of patient 4 has been previously reported[3,6]. It affects the Rag-2 interacting domain of Rag-1 and reduces V(D)J recombination activity by 3 to 4-fold[3]. The *RAG1* L526R mutation of patient 5 is novel.

Finally, the *RAG2* G139R mutation of patient 2 falls in the first β strand of the third kelch motif within the β-propeller structure of the catalytic core of Rag-2, where several other disease-causing mutations have been identified[17,18]. The novel mutations detected in patients 2 and 3 were found to severely reduce, but not completely abrogate, the V(D)J recombination activity (Table 1).

The five patients examined had variable numbers of autologous peripheral blood CD4[+] and CD8[+] T cells (Table 1), indicating that at least limited V(D)J recombination occurred in these patients. Since CD4[+] T cells in OS have been shown to produce Th2 cytokines[19], and CD4[+] iNKT cells also produce Th2 cytokines[20], we asked whether any of the peripheral blood T cells in OS patients were iNKT cells. Using α-GalCer loaded CD1d tetramers, we were unable to detect iNKT cells (Fig. 1), while iNKT cells were present in healthy controls (Fig.1 and Supplementary Figure 1). Lack of iNKT cells in OS patients was confirmed by staining with the 6B11 antibody (which binds to the CDR3 region of human invariant TCR) and by analysis of Vα24[+]/Vβ11[+] T cells (Supplementary Figure 2).

iNKT cells are important in protecting against autoimmune manifestations[21] and graft-versus-host disease (GvHD)[22]. Moreover, they can suppress pathogenic Th1 cells[23]. Numerical or functional defects of iNKT cells have been reported in numerous autoimmune conditions in humans and in mice[10,23]. Therefore, the absence of iNKT cells in OS may contribute to the development of the skin disease and colitis frequently observed in these patients.

In conclusion, our data demonstrate that hypomorphic mutations of the *RAG* genes in humans are not permissive for development of iNKT cells. The contribution of

this abnormality to the pathophysiology of OS could be addressed by adoptive transfer of purified iNKT cells into mice expressing hypomorphic mutations of the *Rag* genes[9,24].

## Authorship

Ponpan Matangkasombut and Muriel Pichavant performed analysis of iNKT cells and contributed to the writing and critical revision of the manuscript. Evelina Mazzolari and Andrea Finocchi were involved in clinical care of patients 2, 3, 4 and 5. Doris E. Saez performed the the in vitro V(D)J recombination analysis, under the supervision of Patricia Cortes. Silvia Giliani performed mutation analysis at the *RAG* loci in patients 2, 3 and 4, Anna Villa and Cristina Sobacchi identified the mutations in patient 5. Dale Umetsu and Luigi D. Notarangelo conceived the study and wrote the manuscript.

The authors declare they have no potential conflict of interest.

Correspondence: Luigi D. Notarangelo, Division of Immunology, Children's Hospital. Karp Building 9th floor, Room 9120, 1 Blackfan Circle, Boston, MA 02115, USA. E-mail: luigi.notarangelo@childrens.harvard.edu

## References

1. Signorini S, Imberti L, Pirovano S, Villa A, Facchetti F, Ungari M, et al. Intrathymic restriction and peripheral expansion of the T-cell repertoire in Omenn syndrome. Blood 1999;94:3468-3478.

2. Rieux-Laucat F, Bahadoran P, Brousse N, Selz F, Fischer A, Le Deist F, et al. Highly restricted human T cell repertoire in peripheral blood and tissue-infiltrating lymphocytes in Omenn's syndrome. J Clin Invest 1998;102:312-321.

3. Villa A, Santagata S, Bozzi F, Giliani S, Frattini A, Imberti L, et al. Partial V(D)J recombination activity leads to Omenn syndrome. Cell 1998;93:885-896.

4. Corneo B, Moshous D, Gungor T, Wulffraat N, Philippet P, Le Deist FL, et al. Identical mutations in RAG1 or RAG2 genes leading to defective V(D)J recombinase activity can cause either T-B-severe combined immune deficiency or Omenn syndrome. Blood 2001;97:2772-2776.

5. Sobacchi C, Marrella V, Rucci F, Vezzoni P, Villa A. RAG-dependent primary immunodeficiencies. Hum Mutat 2006;27:1174-1184.

6. Villa A, Sobacchi C, Notarangelo LD, Bozzi F, Abinun M, Abrahamsen TG, et al. V(D)J recombination defects in lymphocytes due to RAG mutations: severe immunodeficiency with a spectrum of clinical presentations. Blood 2001;97:81-88.

7. Cavadini P, Vermi W, Facchetti F, Fontana S, Nagafuchi S, Mazzolari E, et al. AIRE deficiency in thymus of 2 patients with Omenn syndrome. J Clin Invest 2005;115:728-732.

8. Honig M, Schwarz K. Omenn syndrome: a lack of tolerance on the background of deficient lymphocyte development and maturation. Curr Opin Rheumatol 2006;18:383-388.

9. Marrella V, Poliani PL, Casati A, Rucci F, Frascoli L, Gougeon ML, et al. A hypomorphic R229Q Rag2 mouse mutant recapitulates human Omenn syndrome. J Clin Invest 2007;117:1260-1269.

10. Taniguchi M, Harada M, Kojo S, Nakayama T, Wakao H. The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu Rev Immunol 2003;21:483-513.

11. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K, et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 1997;278:1626-1629.

12. Egawa T, Eberl G, Taniuchi I, Benlagha K, Geissmann F, Hennighausen L, et al. Genetic evidence supporting selection of the Valpha14i NKT cell lineage from double-positive thymocyte precursors. Immunity 2005;22:705-716.

13. Wei DG, Lee H, Park SH, Beaudoin L, Teyton L, Lehuen A, et al. Expansion and long-range differentiation of the NKT cell lineage in mice expressing CD1d exclusively on cortical thymocytes. J Exp Med. 2005;202:239-248.

14. Gauss GH, Lieber MR. Unequal signal and coding joint formation in human V(D)J recombination. Mol Cell Biol 1993;13:3900-3906.

15. Difilippantonio MJ, McMahan CJ, Eastman QM, Spanopoulou E, Schatz DG. RAG1 mediates signal sequence recognition and recruitment of RAG2 in V(D)J recombination. Cell 1996;87:253-262.

16. Wada T, Takei K, Kudo M, Shimura S, Kasahara Y, Koizumi S, et al. Characterization of immune function and analysis of RAG gene mutations in Omenn syndrome and related disorders. Clin Exp Immunol 2000;119:148-155.

17. Corneo B, Moshous D, Callebaut I, de Chasseval R, Fischer A, de Villartay JP. Three-dimensional clustering of human RAG2 gene mutations in severe combined immune deficiency. J Biol Chem 2000;275:12672-12675.

18. Gomez CA, Ptaszek LM, Villa A, Bozzi F, Sobacchi C, Brooks EG,et al. Mutations in conserved regions of the predicted RAG2 kelch repeats block initiation of V(D)J recombination and result in primary immunodeficiencies. Mol Cell Biol 2000;20:5653-5664.

19. Chilosi M, Facchetti F, Notarangelo LD, Romagnani S, Del Prete G, Almerigogna F, et al. CD30 cell expression and abnormal soluble CD30 serum accumulation in Omenn's syndrome: evidence for a T helper 2-mediated condition. Eur J Immunol 1996;26:329-334.

20. Stetson DB. Constitutive cytokine mRNAs mark natural killer (NK) and NK T cells poised for rapid effector function. J Exp Med 2003;198:1069-1076

21. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol 2007;25:297-336.

22. Pillai AB, George TI, Dutt S, Teo P, Strober S. Host NKT cells can prevent graft-versus-host disease and permit graft antitumor activity after bone marrow transplantation. J Immunol 2007;15:6242-6251.

23. Van Kaer, L. α-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles. Nat Rev Immunol 2005;5: 31-42.

24. Khiong K, Murakami M, Kitabayashi C, Ueda N, Sawa S, Sakamoto A, et al. Homeostatically proliferating CD4 T cells are involved in the pathogenesis of an Omenn syndrome murine model. J Clin Invest. 2007;117:1270-1281.

**Legend to Figure**

**Figure 1**. **Flow cytometric analysis of peripheral blood iNKT cells from patients with hypomorphic RAG mutations.** Mononuclear cells (PBMC) from a healthy control (representative of 6 donors) (a) and five patients with hypomorphic mutations of the *RAG* genes (b) were analyzed for the presence of iNKT cells. Leukocytes were enumerated by gating on $CD45^+CD3^+$ cells. iNKT cells were identified using PBS57-loaded CD1d tetramers (right panel) using cells stained with unloaded CD1d tetramers as control (left panel).

**Figure 1**

**Table 1 – Clinical and laboratory features of five infants with hypomorphic *RAG* mutations**

| | Patient number | | | | |
|---|---|---|---|---|---|
| | 1 | 2 | 3 | 4 | 5 |
| Gene mutations | *RAG1* deletion (encompassing also *RAG2*); **M435V** | *RAG2* **G139R;G139R** | *RAG1* **G392E**;L732fs | *RAG1* R332X;**R561H** | *RAG1* **L526R**, S117fs |
| VDJ recombination activity (% of wild-type)[a] | n.d. | 1.5 | 1.5 | n.d. | n.d. |
| Age at onset | first month | 6 months | birth | 5 months | 2 months |
| Erythrodermia/pachydermia | + | + | + | - | + |
| Liver/ Spleen enlargement | - | - | + | - | + |
| Lymphadenopathy | - | - | + | - | - |
| Diarrhea | + | + | + | + | - |
| Oedemas | + | - | + | - | - |
| Infections | Achromoacter xylosoxidans sepsis | Pneumonia, sepsis | Candida, Klebsiella | Candida; Pseudomonas | Interstitial pneumonia |
| ALC (cells x$10^{-9}$/L) | 62.3 | 0.3 | 3.7 | 0.4 | 25.7 |
| CD3 (%) | 96 | 20.9 | 83.9 | 47.4 | 91 |
| CD4 (%) | 32 | 10.4 | 69.6 | 19.0 | 77 |
| CD8 (%) | 62 | 9.0 | 12.9 | 6.3 | 10 |
| CD19 (%) | 0 | 1.1 | 0.4 | 0.1 | 0 |
| CD16 (%) | 2 | 60.0 | 15.6 | 42.7 | 4 |
| CD4+ CD45R0+/CD4+ (%) | n.d. | 82.3 | 96.0 | 85.8 | 100 |
| Response to PHA (cpm x$10^{-3}$) | 39.2 (179) | 1.6 (121) | 8.0 (134) | 6.5 (112) | 9.4 (57) |
| IgG (mg/dL) | 41 | <100 | 121 | 14 | 240 |
| IgA (mg/dL) | <7 | <5 | <6 | 6.1 | 10 |
| IgM (mg/dL) | <4 | <5 | 25 | 4 | 24 |
| IgE (kU/L) | 128 | n.d. | n.d. | <19 | >5000 |

[a]For patients #2 and 3, V(D)J recombination activity was evaluated using a plasmid-based colony formation assay, as described[14].

Hypomorphic mutations are indicated in bold. Values of proliferative response to PHA in normal controls are indicated in parentheses.

ALC: absolute lymphocyte count; PHA: phytoemagglutinin.